The Centers for Medicare and Medicaid Services has fundamentally altered the landscape for structural heart intervention by finalizing a national coverage determination that extends Medicare reimbursement for transcatheter aortic valve replacement (TAVR) to patients with severe aortic stenosis who have not yet developed symptoms. The Thursday announcement marks a watershed moment for preventive cardiac care, enabling intervention before irreversible heart damage occurs while establishing new evidence requirements that will shape the procedure's evolution.

Policy Shift Follows FDA Approval and Clinical Evidence

The CMS decision follows Edwards Lifesciences' April 2025 FDA approval for expanded use of its Sapien 3 TAVR platform in asymptomatic patients, supported by the EARLY TAVR study demonstrating superior outcomes compared to watchful waiting. Edwards had requested policy reconsideration in 2019, setting in motion a multi-year regulatory process that culminated in this coverage expansion.

The finalized policy eliminates coverage with evidence development (CED) requirements for symptomatic patients, streamlining access for the traditional TAVR population. However, CMS mandates evidence generation for the newly covered asymptomatic group, requiring structured data collection to inform long-term outcomes and optimal patient selection criteria. This dual approach reflects CMS's effort to balance expanded access with rigorous evaluation of early intervention benefits.

Market Implications for Structural Heart Leaders

The coverage expansion carries substantial financial implications for TAVR manufacturers operating in a global market valued at over $7 billion. For Edwards Lifesciences, where TAVR represents approximately 75% of total revenues, the asymptomatic patient population represents a significant growth opportunity. The company has maintained its 2026 financial guidance, with longer-term projections expected at its December investor conference.

Competitor Medtronic, for which TAVR accounts for 5.5% of revenues, also stands to benefit from the expanded addressable market. Meanwhile, CMS indicated it will review TAVR coverage for aortic regurgitation, with a proposal expected by March 2027. This timeline follows FDA approval of JenaValve's Trilogy system in March 2025, marking the first TAVR device cleared for aortic regurgitation and potentially opening another coverage frontier.

Evidence Requirements Shape Clinical Implementation

The evidence development mandate for asymptomatic patients means Medicare beneficiaries seeking early intervention will likely receive treatment within structured programs that systematically collect outcomes data. This requirement creates opportunities for digital health technologies, including AI-powered clinical decision support systems that could optimize patient selection, predict procedural success, and identify individuals most likely to benefit from early valve replacement versus continued monitoring.

Healthcare providers will need to balance the clinical appeal of preventing disease progression against the administrative requirements of participating in evidence generation programs. The policy framework suggests CMS views asymptomatic TAVR as promising but requiring additional real-world validation to establish long-term value and appropriate utilization patterns.

The coverage determination represents a significant step toward earlier intervention in structural heart disease, potentially preventing the cardiac remodeling and functional decline that occur as aortic stenosis progresses. As evidence accumulates from the newly covered asymptomatic population, the data may inform refined treatment algorithms and risk stratification approaches that further personalize valve replacement timing decisions.

Sources

  1. CMS expands TAVR Medicare coverage to asymptomatic patients — MedTech Dive